%0 Journal Article
%T Abstract QS12: Deferoxamine Diminishes Breast Cancer Proliferation and Enhances Irradiated Breast Reconstruction: An Antitumorigenic Mechanism Defined
%J Archive of "Plastic and Reconstructive Surgery Global Open".
%D 2019
%R 10.1097/01.GOX.0000558432.68210.65
%X PURPOSE: Radiation plays an essential role in the oncologic management of triple-negative breast cancer, but patients who undergo radiotherapy experience significantly more wound complications during the reconstructive process. Deferoxamine is an FDA-approved iron chelator with immense potential to up-regulate angiogenesis and improve reconstructive outcomes. More specifically, the ability of deferoxamine to mitigate the deleterious effects of radiation on skin and soft tissue has been shown to enhance expander-based irradiated breast reconstruction, increase fat graft retention, and facilitate irradiated transverse rectus abdominis myocutaneous flap survival. The purpose of this study is to determine the impact of deferoxamine on breast cancer cell proliferation in-vitro, in order to delineate oncologic safety concerns regarding the utilization of deferoxamine as a regenerative therapeutic
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504510/